The Battle Against Hormone-Refractory Prostate Cancer: Is Satraplatin the Second-Line Savior?

ISSN： 1176-3469

Source： Pharmaceutical & Diagnostic Innovation, Vol.4, Iss.5, 2006-01, pp. : 7-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hormone-Refractory Prostate Cancer: Where are We Going?

By Giuseppe Di Lorenzo

Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. : 1109-1124

Adis International

Access to resources Recommend Favorite

Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types: Pharmacological Properties and Clinical Evaluation

By McKeage Mark J.

Drugs, Vol. 67, Iss. 6, 2007-01 ,pp. : 859-869

Adis International

Access to resources Recommend Favorite

Which drug combination for hormone-refractory prostate cancer?

By Doggrell Sheila A

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 667-670

Informa Healthcare

Access to resources Recommend Favorite

Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-05 ,pp. : 915-920

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel: In Hormone-Refractory Metastatic Prostate Cancer

By McKeage Kate Keam Susan J.

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2287-2294

Adis International

Access to resources Recommend Favorite